Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Curr Opin Urol. 2020 Jul;30(4):602-609. doi: 10.1097/MOU.0000000000000768.
The role of metastasectomy in the management of metastatic renal cell carcinoma (mRCC) remains controversial. The aim of this review is to summarize and evaluate the recent findings about the surgical treatment of patients with mRCC focusing on the literature published in the last 2 years.
Despite the lack of randomized controlled trials, the benefit of metastasectomy in term of cancer-specific and overall survival have been demonstrated in large observational studies. Results of ongoing clinical trials evaluating the impact of combination of surgical and systemic therapies are eagerly awaited and may shed the light on a new treatment armamentarium in this subset of patients.
Several novel systemic agents have emerged and is continuously changing the treatment paradigm in patients with advanced RCC. However, surgical resection of the primary tumor and metastatic deposits represents a definitive cure option in well selected patients.
转移性肾细胞癌（mRCC）的转移灶切除术的作用仍存在争议。本综述的目的是总结和评估最近关于 mRCC 患者手术治疗的研究结果，重点关注过去 2 年发表的文献。
尽管缺乏随机对照试验，但大型观察性研究表明，转移灶切除术在癌症特异性和总体生存方面具有益处。正在评估手术和系统治疗联合影响的临床试验结果备受期待，可能为这部分患者的新治疗方法提供依据。
几种新型的系统治疗药物已经出现，不断改变着晚期肾细胞癌患者的治疗模式。然而，对于选择合适的患者，手术切除原发肿瘤和转移灶仍是一种确定性的治疗选择。
